Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Maze Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a separate examiner and art unit, indicating three distinct examination paths.
ROMERO, KRISTEN WANG is the busiest examiner, with 1 pending matter. Counsel should use matter-specific response strategies and avoid assuming that one examiner’s approach applies across the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 58d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 58d overdue |
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | ROMERO, KRISTEN WANG | 15d |
| 18263118 | VECTORS COMPRISING STUFFER POLYNUCLEOTIDE SEQUENCES | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1632 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | ROMERO, KRISTEN WANG | 1624 | — | Non-Final OA | 15d | Pending | Oct 11, 2023 |
| 18263118 | VECTORS COMPRISING STUFFER POLYNUCLEOTIDE SEQUENCES | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 1636 | §101§102§103§112DP | Final Rejection | 58d overdue | Pending | Jul 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaze Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Kristen Wang Romero has the most, with 1 of Maze Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
